Ianalumab (VAY736) Phase II Trial published

[markt]

Ianalumab (VAY736) is an anti-B-cell activating factor (BAFF) receptor fully human IgG1 monoclonal antibody, engineered for direct ADCC-mediated B-cell depletion, thus providing a dual mode of action and targeted approach to treat pSS.

https://www.novartis.com/stories/patient-perspectives/targeting-roots-sjogrens-syndrome

The defined primary endpoint assessing ESSDAI was met, showing statistically significant dose-response for ianalumab with clinically important improvement over placebo at the highest tested dose. The preliminary safety profile was good. Future analysis will focus on PK and immunogenicity, salivary and tear flow parameters and the exploration of ESSDAI domains, and the ongoing-blinded treatment period up to Week 52.

Looking forward to this one, as it is has been described as "along the lines of Rituximab" by my Hopkins Rheumatologist, whose name coincidentally appears in the publication. 

[bloodless]

Thank you for posting this article. I can't wait 'till this drug is available!